3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
59
Recruiting
25
Terminated
24
Active not recruiting
14
Withdrawn
8
Unknown
7
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
2
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
425
Neoplasms
284
Carcinoma, Non-Small-Cell Lung
274
Colorectal Neoplasms
236
Prostatic Neoplasms
173
Lung Neoplasms
171
Carcinoma, Hepatocellular
157
Stomach Neoplasms
126
Leukemia, Myeloid, Acute
120
Pancreatic Neoplasms
118
Multiple Myeloma
106
Recurrence
100
Uterine Cervical Neoplasms
97
Squamous Cell Carcinoma of Head and Neck
89
Neoplasm Metastasis
88
Rectal Neoplasms
87
Ovarian Neoplasms
81
Triple Negative Breast Neoplasms
78
Small Cell Lung Carcinoma
72
Head and Neck Neoplasms
70
Brain Neoplasms
70
Glioblastoma
65
Esophageal Neoplasms
65
Endometrial Neoplasms
59
Colonic Neoplasms
59
Melanoma
56
Hematologic Neoplasms
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Motor Activity
48
Glioma
48
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Interventional
×
Lymphoproliferative Disorders
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled